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Abstract
Epidemiologic data regarding health care acquired pneumonia (HAP) and ventilator-associ-
ated pneumonia (VAP) from Nepal are negligible. We conducted a prospective observa-
tional cohort study in the intensive care unit (ICU) of a major tertiary hospital in Nepal
between April 2016 and March 2018, to calculate the incidence of VAP, and to describe clini-
cal variables, microbiological etiology, and outcomes. Four hundred and thirty-eight patients
were enrolled in the study. Demographic data, medical history, antimicrobial administration
record, chest X-ray, biochemical, microbiological and haematological results, acute physiol-
ogy and chronic health evaluation II score and the sequential organ failure assessment
scores were recorded. Categorical variables were expressed as count and percentage and
analyzed using the Fisher’s exact test. Continuous variables were expressed as median
and interquartile range and analyzed using Kruskal-Wallis rank sum test and the pairwise
Wilcoxon rank—sum test. 46.8% (205/438) of the patients required intubation. Pneumonia
was common in both intubated (94.14%; 193/205) and non-intubated (52.36%; 122/233)
patients. Pneumonia developed among intubated patients in the ICU had longer days of
stay in the ICU (median of 10, IQR 5–15, P< 0.001) when compared to non-intubated
patients with pneumonia (median of 4, IQR 3–6, P< 0.001). The incidence rate of VAP was
20% (41/205) and incidence density was 16.45 cases per 1,000ventilator days. Mortality
was significantly higher in patients with pneumonia requiring intubation (44.6%, 86/193)
than patients with pneumonia not requiring intubation (10.7%, 13/122, p<0.001, Fisher’s
exact test). Gram negative bacteria such as Klebsiella and Acinetobacter species were the
dominant organisms from both VAP and non-VAP categories. Multi-drug resistance was
highly prevalent in bacterial isolates associated with VAP (90%; 99/110) and non-VAP cate-
gories (81.5%; 106/130). HAP including VAP remains to be the most prevalent hospital-
acquired infections (HAIs) at Patan hospital. A local study of etiological agents and out-
comes of HAP and VAP are required for setting more appropriate guidelines for manage-
ment of such diseases.
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Introduction
Pneumonia is clinically defined as the presence of a new lung infiltrate with evidence that the
infiltrate is triggered by an infectious agent such as, the new onset of fever, purulent sputum,
or leukocytosis [1]. Healthcare acquired pneumonia (HAP) is an infection of the pulmonary
parenchyma that develops>48 hours of admission to a health care facility and is commonly
caused by pathogens that circulate in hospital settings [2]. In clinical practice, HAP is sus-
pected when a patient presents with fever, impaired oxygenation, and suppurative secretions
[3]. HAP is an important infectious disease worldwide and is associated with high morbidity,
mortality, and additional health system expenditure [4]. In the US, the prevalence of HAP has
been estimated to be1.6% of all hospital admissions, representing a rate of 3.63 cases per 1,000
patient-days [5]. Epidemiologic data regarding HAP in Asia are scarce; however, the incidence
of HAP is predicted to be high across Asia and especially problematic in intensive care units
(ICUs), where the proportion of ICU-acquired respiratory infections ranges from 9% to 23%
of admissions [6].
Ventilator-associated pneumonia (VAP) is a subtype of HAP that develops in ICU patients
who have been mechanically ventilated for at least 48 hour [2, 7, 8]. VAP remains one of the
most common infections in patients requiring invasive mechanical ventilation and is the lead-
ing cause of ICU mortality [2, 7]. The reported prevalence of VAP vary from 5 to 40% of venti-
lated patients depending on country, ICU type, and criteria used to diagnose VAP [9]. In high-
income countries, a combination of surveillance, education, and tailored intervention and pre-
vention bundles have led to a major reduction in VAP [10]. However, even with the imple-
mentation of such programs, VAP is still commonly reported in the US [7]. In Asia there are
limited data on incidence of VAP, the causative pathogens, and their antimicrobial susceptibil-
ity profiles [6, 11].A meta-analysis which encompassed 88 studies from 22 Asian countries
from 2008 to 2018 indicated that the pooled incidence density of VAP in low-middle-income
countries (LMICs) (18.5 per 1,000 ventilator-days) was more than twice that in high-income
countries (9.0 per 1,000 ventilator-days) [12].
VAP has received little attention in LMICs until relatively recently [13]. In a low income
country, like Nepal, where the incidence of infectious disease is high and strategies for control
and prevention are weak, the opportunity for nosocomial infection is significantly higher [11,
14–16].This problem is further exacerbated by antimicrobial resistance (AMR) in organisms
such as Acinetobacter baumannii and Klebsiella pneumoniae, which are responsible for a large
proportion of nosocomial infections and commonly multi-drug resistant (MDR) [17, 18].
A delayed diagnosis and delay in initiating appropriate therapy in VAP may be associated
with poor outcomes [2, 19–21]. Therefore, an early and accurate diagnosis is fundamental in
the management of patients with VAP. In order to develop effective therapeutic strategies to
optimize the use of antimicrobial agents we need a better understanding of the local pathogens
causing. Therefore, we performed a prospective study to describe some epidemiological fea-
tures of HAP among patients admitted to the ICU of major tertiary hospital in Kathmandu,
Nepal. We measured the incidence rate of VAP, investigated the antimicrobial susceptibility
profiles of the etiological agents, and compared clinical profiles associated with HAP/VAP
mortality.
Materials and methods
Ethics approval and consent to participate
This study was approved by Nepal Health Research Council (NHRC) (Reference number 11/
2016,Date: 11 March 2016) and Oxford Tropical Research Ethics Committee (OxTREC 32–16,
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Date:19 October 2016). Adult patients admitted in the ICU or next-of-kin of the patient were
approached for written informed consent to participate in this study.
Setting and study design
This was a prospective observational cohort study conducted in the ICU of Patan hospital
between April 2016 and March 2018. Patan hospital is a 450-bed tertiary care referral teaching
hospital with 15 ICU beds, located in the Lalitpur Metropolitan area of the Kathmandu valley
in Nepal.
Study structure
All adult patients,� 18 years of age admitted to the ICU were eligible to participate in the
study. Adult patients admitted in the ICU or next-of-kin of the patient were approached for
written informed consent to participate. Patients who denied consent and under the 18 years of
age were not included in the study. Upon recruitment, demographic data, medical history, anti-
microbial administration record, chest X-ray or other imaging findings, biochemical, microbio-
logical and haematological results, and clinical parameters were recorded in a case report form
(CRF). The acute physiology and chronic health evaluation (APACHE) II score and the sequen-
tial organ failure assessment (SOFA) score were recorded from the biochemical findings of the
day of admission. Daily observation of the individual was conducted and CRF completed until
an outcome of discharge, death, transfer to another ward or development of VAP.
VAP was defined by following the modified US Centers for Disease Control and Prevention cri-
teria which requires to fulfill radiographic, systemic, and pulmonary criteria [16, 22–24] “Fig 1”.
The day when the patient fulfilled the criteria of VAP was taken as day 0 of VAP diagnosis.
These VAP confirmed patients were followed up on day 3, day 7, and day14. During these vis-
its comparable clinical information was collected via hospital records. The final follow up was
conducted on day 30 by phone if the patient was discharged, or in person if the patient was
still in the hospital. Final diagnosis or working diagnosis if still under admission were recorded
in the patient CRF.
Sample collection for microbiological culture
Respiratory samples [either tracheal aspirates (TA), bronchoalveolar lavage (BAL), or sputum]
and blood samples were obtained from enrolled patients for microbiological culture. A respira-
tory sample of either TA or BAL was obtained from all patients before the diagnosis of VAP.
The decision for BAL or TA samples were at the discretion of the treating physician.
Collection of TA sample
TA samples were collected as previously described, following local standard operating proce-
dures [25]. Specimens were transported to the microbiology laboratory, and processed within
2 hours of collection. The tracheal aspirate specimens were examined by Gram staining, and
the aspirate fluid was diluted 1:1 with Sputasol (Oxoid) and incubated at 37˚C, with periodic
agitation, until liquefaction. The sample was diluted (1:1, 10−1 and 10−2) using maximum
recovery diluent (Oxoid), and 20 ml 1:1 diluent was inoculated onto blood agar and chocolate
agar plates. Additionally, 20μl of the 10−1 and 10−2 dilutions was plated onto MacConkey
media and blood agar base (Mast diagnostics, UK). Inoculated media were incubated at
37˚Cand examined after 24 and 48 h of incubation. The threshold used to discriminate
between infection and colonization was�1x105 colony forming unit (CFU)/ ml-1 (i.e., 20 col-
onies on either media from the 10−2 dilution). Colonies above this threshold were identified
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using biochemical tests following standard operating protocol of Patan Hospital. In the inter-
pretation of results, each colony corresponded to 20,000 CFU/ml, and it was considered to be
TA positive when the count was�105CFU/ml [26].
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed using the Kirby Bauer disc diffusion
method. The inhibitory zone sizes were interpreted according to the Clinical and Laboratory
Standards Institute (CLSI) 2018 guidelines. Mueller–Hinton agar and antimicrobial discs were
purchased from Mast Diagnostics, UK. Escherichia coli ATCC 25922 and Staphylococcus
aureus ATCC 25923 were used as controls for these assays. The antimicrobials tested against
Acinetobacter spp., Pseudomonas spp., and the Enterobacteriaceae were amikacin (30 mg),
piperacillin/tazobactam (100/10 mg), imipenem (10 mg), ofloxacin (5 mg), and ceftriaxone (30
mg). An isolate was defined as MDR when it was non-susceptible to at least one agent in�3
antimicrobial categories[CLSI guidelines (2018)] [27].Gram positive organisms were tested
against co-trimoxazole (1.25/ 23.75 mg), penicillin (10 mg), gentamicin (10 mg), erythromycin
(15mg) and oxacillin (1 mg).
Statistical analysis
Data recorded onto a case record form were entered into a CliRes database system protecting
participant information. Verification was done by double entry. Data analysis was performed
in R Software (version 3.2). Categorical variables were expressed as count and percentage and
analyzed using the Fisher’s exact test. Continuous variables were expressed as median and
interquartile range and analyzed using Kruskal-Wallis rank sum test and the pairwise Wil-
coxon rank—sum test. Each variable with a p- value < 0.05 was considered a significant vari-
able. VAP incidence was calculated as follows: (Number of cases with VAP/Total number of
patients who received MVx100) = VAP rate per 100 patients. VAP incidence density was cal-
culated as follows: (Number of cases with VAP/Number of ventilator days) x 1000 = VAP per
1,000 ventilator days. Flow diagram of the study enrollment procedure and categorization into
five categories is shown in “Fig 2”.
Results
Baseline characteristics
Four hundred and thirty-eight patients between April 2016 and March 2018were hospitalized
in the ICU and enrolled in the study. The patients were between the ages of 18 and 95 years
and 48.9% (214) were male and 51.1% (224) were female “Table 1”.
The total numbers of participants in each of the five categories were I-P-V- = 111, I-P+V- =
122, I+P-V- = 12, I+P+V- = 152, and I+P+V+ = 41, who had median ages of 48, 62.5, 35.5,
57.5, and 59.5years, respectively. More than 50% of participants in all five categories had co-
morbidities at the time of admission in the ICU with>15% of the participants in each category
Fig 1. Flow diagram for VAP definition. Firstly, a deterioration in ventilation following a period of stability defined
according to positive end expiratory pressure (PEEP):� 2 days of stable or decreasing daily minimum PEEP followed
by a rise in daily minimum PEEP of� 2.5 cm H2O, sustained� 2 calendar days; or FiO2:�2 days of stable or
decreasing daily minimum fraction of inspired oxygen(FiO2) followed by a rise in daily minimum FiO2� 0.15 points,
sustained� 2 calendar days. Secondly, systemic signs of fever>38˚C or<36˚C or white blood cell count>12×109/L
or<4×10 9/L were required. Final criteria was an increased/new purulent tracheal aspirate (TA) samples/
tracheobronchial secretions or�25 neutrophils per low power field (10 objective) on Gram stain of tracheal aspirate
and either new and persistent infiltrates, consolidation, or cavitation as read by two study physicians on chest X-ray, or
the decision to commence new antibiotic therapy.
https://doi.org/10.1371/journal.pone.0259634.g001
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Fig 2. Flow diagram of the study enrollment procedure and categorization into five categories. Patients enrolled in the study were into five groups depending upon
intubation, pneumonia development, and VAP development: These were: I-P-V- (not intubated, no pneumonia), I-P+V- (not intubated, but pneumonia developed), I
+P-V- (intubated but no pneumonia), I+P+V-(intubated and pneumonia developed, but VAP not confirmed), and I+P+V+(VAP confirmed). The flow diagram of the
study enrollment procedure and categorization into five categories is shown in “Fig 2”.
https://doi.org/10.1371/journal.pone.0259634.g002
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having had a history of hospital admission in the past 90 days with antimicrobial use ranging
from 9.8% (4/41 in the I+P+V+ group) to 35.5% (54/152 in the I+P+V- group). The median
SOFA scores ranged from 3 to 10, with the highest scores being observed in the VAP group
(median of 10, IQR 7–11). The median APACHE II score ranged from 10 to 18; the highest
score was observed in the non-VAP group 18 (IQR 13–24).
Association of different variables with intubation and pneumonia
In total, 29.7% (130/438) of patients had a diagnosis of pneumonia when admitted in the ICU
and 46.8% (205/438) of patients required intubation. The most common requirement for intu-
bation was failure to oxygenate (24.4%; 50/205), followed by failure to maintain or protect the
airway (99%; 39/205). Pneumonia was common in both the intubated (94.14%; 193/205) and
the non-intubated (52.36%; 122/233) patients. Pneumonia in intubated patients in the ICU
was associated with longer days of stay (median of 10, IQR 5–15, p< 0.001) when compared to
non-intubated patients with pneumonia (median of 4, IQR 3–6, p< 0.001). SOFA and
APACHE II scores were also significantly higher among the patients that then on-intubated
patients (p<0.05; Kruscal-wallis rank sum test) “Table 2”.
Table 1. Baseline characteristics of patients enrolled in the study.
Variables I-P-V- (111) I-P+V- (122) I+P-V- (12) I+P+V- (152) I+P+V+ (41)
Age (years) 48 (30–62) 62.5 (48.5–72) 35.5 (23.3–50.3) 57.5 (35–72) 59.5 (42.8–76.3)
Weight (Kilogram) 59.5 (50–65) 57 (49.5–64) 60 (50.5–70.5) 58 (50–65) 58 (49–62)
M:F 57:54 53:69 7:5 77:75 20:21
SOFA 3 (2–5) 3 (2–5) 6.5 (4–10) 8 (5–11) 10 (7–11)
APACHE 10 (6–14) 11 (7.3–14) 12 (6.8–15.3) 18 (13–24) 17 (13–22)
Comorbidity 60 (54.1%) 90 (73.8%) 7 (58.3%) 91 (59.9%) 27 (65.9%)
Hospital previous 90 days 22 (19.8%) 19 (15.6%) 3 (25%) 38 (25%) 7 (17.1%)
Antibiotics in last 90 days 11 (9.9%) 28 (23%) 3 (25%) 54 (35.5%) 4 (9.8%)
Values given are median (IQR) or count (percent).
I-P-V- (Non intubated, no pneumonia), I-P+V- (non- intubated, pneumonia developed), I+P-V- (intubated, no pneumonia), I+P+V- (intubated, pneumonia but not
VAP also called non–VAP), I+P+V+ (intubated, pneumonia and VAP confirmed).
https://doi.org/10.1371/journal.pone.0259634.t001
Table 2. Kruskal-wallis rank sum test for the variables associated with intubation and pneumonia.
Variables IntPosPneum NonIntPosPneum p—value
I+P+V(V+and V-) I-P+V-
(193) (122)
Days in Hospital 11 (7–17) 5 (3–7) <0.001
Days in ICU 10 (5–15) 4 (3–6) <0.001
Days in Intubation 9 (5–15) NA NA
FiO2 50 (40–80) 36 (29–41) <0.001
PaO2 79 (48.2–114) 68.1 (53.7–88) 0.056
Temperature 98 (97.2–99.2) 98 (97.2–98.4) 0.027
SOFA 8 (5–11) 3 (2–5) <0.001
APACHE 18 (13–23) 11 (7.25–14) <0.001
Mortality 86/193 (44.6%) 13/122 (10.7%) <0.001
Values given are median (IQR) or count (percent). Kruskal-Wallis rank sum test for median (IQR). Fisher’s Exact Test for count (percent). I+P+ (intubated,
pneumonia) and I-P+ (non- intubated, pneumonia developed).
https://doi.org/10.1371/journal.pone.0259634.t002
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Incidence density of VAP
Out of 205 patients requiring mechanical ventilation during their stay in ICU, 41 patients were
diagnosed with VAP (20%), equating with a total incidence density of 16.45 cases per 1,000
ventilator days.
Factors associated with VAP confirmed cases
We aimed to identify factors associated with VAP in the VAP confirmed group (I+P+V+)
“Table 3”. VAP was significantly associated with the duration of stay in the hospital (median
18 days, IQR 11–27, p<0.001), the duration of stay in ICU (median16 days, IQR 10–25,
p<0.001), number of days of intubation (median 17 days, IQR 11–27, p<0.001), fraction of
inspired oxygen(FiO2) (median 60, IQR 40–100, p<0.001), APACHE II score (median 17,
IQR 13–22 p<0.001), SOFA score (median 10, IQR 7–11, p<0.001) and PaO2 (median 70.6,
IQR 52.3–102, p<0.04).
A pairwise Wilcoxon signed rank test was performed among the five defined categories to
identify significance between the groups “Fig 3”. The number of days of hospital stay, the num-
ber of days of ICU stay, APACHE II score, and SOFA score were all significantly higher in the
I+P+V+ and I+P+V- groups than in the I-P-V- group (p< 0.001).
Mortality
Mortality was significantly higher in patients with pneumonia requiring intubation than
patients with pneumonia not requiring intubation (44.6% (86/193) vs. 10.7%, (13/122)
p<0.001, Fisher’s exact test) “Table 2”. Between the groups, the highest mortality (58.5%; 24/
41) was observed among VAP patients (I+P+V+) followed by non-VAP (I+P+V-) patients
(40.8%,62/152); and lowest mortality (3.7%; 4/109) was observed among patients who neither
required intubation nor had pneumonia during their stay in the ICU (I-P-V-)(p< 0.001; Krus-
kal wallis test) “Table 3”.
Microbiology of VAP and non- VAP
A total of 110 samples from those with confirmed VAP(I+P+V+) and 130 samples from those
without-VAP category (includes all categories except I+P+V+) were subjected to microbiolog-
ical cultured. The majority of these samples were TA samples; 81/110 in VAP category and 63/
130 in non-VAP category.
Table 3. Kruskal-Wallis rank sum test for the variables associated with different categories.
I-P-V- (n = 111) I-P+V- (n = 122) I+P-V- (n = 12) I+P+V- (n = 152) I+P+V+ (n = 41) p—value
Days in Hospital 4 (3–6) 5 (3–7) 5 (2.75–7) 10 (7–14) 18 (11–27) <0.001
Days in ICU 3 (2–6) 4 (3–6) 4.5 (2.75–6) 9 (5–12) 16 (10–25) <0.001
Days in Intubation NA NA 4 (2.75–7.25) 7.5 (4–11) 17 (11–27) <0.001
FiO2 29 (21–34) 36 (29–41) 40 (30–41) 50 (40–70) 60 (40–100) <0.001
PaO2 85 (65.8–111.4) 68.1 (53.7–88) 103 (64–150.5) 82.5 (48.1–119) 70.6 (52.3–102) 0.041
Temperature 98 (97–98.7) 98 (97.2–98.4) 98.2 (97–99.2) 98 (97.1–99.15) 98.6 (98–99.2) 0.085
SOFA 3 (2–5) 3 (2–5) 6.5 (4–10) 8 (5–11) 10 (7–11) <0.001
APACHE 10 (6–14) 11 (7.25–14) 12 (6.75–15.25) 18 (13–24) 17 (13–22) <0.001
Mortality 4/109(3.7%) 13/122(10.7%) 3/12 (25%) 62/155 (40%) 24/41 (58.5%) <0.001
Values given are median (IQR) or count (percent). Kruskal-Wallis rank sum test for median (IQR).
Fisher’s Exact Test for count (percent).
https://doi.org/10.1371/journal.pone.0259634.t003
PLOS ONE Health care acquired pneumonia in Nepal
PLOS ONE | https://doi.org/10.1371/journal.pone.0259634 November 17, 2021 8 / 16
PLOS ONE Health care acquired pneumonia in Nepal
PLOS ONE | https://doi.org/10.1371/journal.pone.0259634 November 17, 2021 9 / 16
Gram negative bacteria were the dominant organisms from both VAP and non-VAP
patients “Table 4”, “Fig 4”). Klebsiella species was the most common bacteria associated with
VAP (n = 36,32.7%) followed by Acinetobacter species (n = 35, 31.8%).Acinetobacter species
was the predominant organism (n = 48, 36.9%) isolated from those without-VAP, followed by
Klebsiella species (n = 28, 21.5%).Klebsiella species was more likely to be isolated from VAP
patients (OR1.76, 95%CI 0.96–3.3,p value 0.05).
MDR in VAP and non-VAP categories
MDR was prevalent in all bacterial isolates from both VAP and non-VAP categories. The dis-
tribution of MDR isolates from various VAP and non-VAP samples are presented in “Fig 5”.
90% (n = 99/110) of the isolates from various VAP samples and 81.5% (n = 106/130) of the
non-VAP isolates were MDR. The data was suggestive of association of MDR with the VAP
isolates but this was none significant (OR 2.03, 95%CI 0.90–4.85, p 0.07).
Discussion
The data on HAP from prospective studies are scant notably from LMIC setting. Our study
showed that HAP was common in our ICU setting regardless of intubation requirement
[94.14% (193/205) among intubated and 52.36% (122/233) among non-intubated patients]
indicating that these pneumonia cases may be a common HAI at Patan hospital. In addition to
this, at least 16% of the patients from all the categories have had a visit to the hospital in the
past 90 days and 50% of the patients had co-morbidities “Table 1” mainly chronic respiratory
illness such as chronic obstructive pulmonary disorder. As a result, antibiotic usage was also
common. Pneumonia as HAP was also common in a Malaysian study where,21% of HAP
infections were pneumonia [6].
The complex interplay between the endotracheal tube, presence of risk factors, virulence of
the invading bacteria and host immunity largely determine the development of VAP [28].The
diagnosis of VAP is traditionally based on clinical symptoms and radiographic criteria that
require further bacteriological confirmation. However, it has been demonstrated that these cri-
teria are not sensitive or specific [8]. There is no gold standard for the diagnosis of VAP how-
ever, the qualitative method of culturing the tracheobronchial aspirate samples is said to be
better at differentiating colonization and actual infection.
Despite recent advances in microbiological tools, the epidemiology and diagnostic criteria
for VAP are still controversial, complicating the interpretation of treatment, prevention, and
Fig 3. Pairwise Wilcoxon signed rank test performed among the five defined categories to identify significance
between the groups. I = intubated, P = pneumonia, V = VAP. P-value from pairwise wilcox-test with bonferroni
correction.
https://doi.org/10.1371/journal.pone.0259634.g003
Table 4. Etiology of VAP and non-VAP specimens.
Isolates VAP (n = 110) Non-VAP (n = 130) OR (95%CI) p-value
Acinetobacter spp 35 (31.8%) 48 (36.9%) 0.8 (0.45–1.4) 0.42
Klebsiella spp 36 (32.7%) 28 (21.5%) 1.76 (0.96–3.3) 0.05
Pseudomonas spp 14 (12.7%) 17 (13.1%) 0.97 (0.42–2.21) 1
E. coli 11 (10%) 18 (13.8%) 0.69 (0.28–1.64) 0.43
Enterobacter spp 5 (4.5%) 8 (6.2%) 0.73 (0.18–2.61) 0.78
Coagulase negative Staphylococcus (CoNS) 7 (6.4%) 3 (2.3%) 2.9 (0.6–17.6) 0.19
S. aureus 0 (0%) 5 (3.8%) NA NA
https://doi.org/10.1371/journal.pone.0259634.t004
PLOS ONE Health care acquired pneumonia in Nepal
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Fig 4. Etiology of VAP and non-VAP specimen.
https://doi.org/10.1371/journal.pone.0259634.g004
Fig 5. MDR isolates in VAP and non-VAP specimen.
https://doi.org/10.1371/journal.pone.0259634.g005
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outcomes studies [9]. Data on rates of VAP, the common associated pathogens, and their anti-
microbial susceptibility profiles from Asia are limited [12]. Pooled incidence density of VAP
was 18.5 per 1000 ventilator days in high in Asian LMIC countries [12]. This finding is similar
to our study where we observed the incidence rate of VAP of 20% (n = 41/205) with a total of
incidence density of 16.45 per 1000 ventilator days. However, some other Asian countries have
reported a lower VAP incidence (9.9%) and VAP density (8.7/1000 ventilator days) [16].
Meta- analysis study from mainland China reported that the cumulative incidence of VAP was
23.8% [29]. In contrast, studies from India have reported the higher incidence density of VAP
of 39.6% to 40.1% [30, 31].Such reported incidences vary widely from 5 to 40% depending on
the setting and diagnostic criteria [9] indicating that the incidence rates vary not only between
countries but also among different settings within a country. In high-income countries, a com-
bination of surveillance, education, and tailored intervention and prevention bundles have led
to a reduction in the incidence of VAP [32].
Gram negative bacteria were the dominant organisms from both VAP and non-VAP cate-
gories. Klebsiella species was the most common bacteria associated with VAP followed by Aci-
netobacter species Among non-VAP category, Acinetobacter species was the predominant
organism followed by Klebsiella species (n = 28, 21.5%). Klebsiella species was more likely to
be isolated from VAP category). We did not find major differences in the etiologic agents of
VAP and non-VAP organism and their antimicrobial susceptibility profiles. However, there
was a suggestive association of MDR with VAP isolates. Similar findings have been reported
from other studies where the leading pathogens are A. baumannii, P. aeruginosa and K. pneu-
moniae [33, 34]. In a large meta-analysis of 88 studies analyzing VAP in adults in Asia, it was
revealed that A. baumannii was the most common organism in the LMIC group and the pro-
portion due to this organism gradually reduced as income levels increased, and S. aureus and
P. aeruginosa were the most common in the high income country group [12].Studies on VAP
from other Asian countries also have reported A. baumannii to be the most common isolate
[35].
One of the differences between our data and reports from Western countries was the pro-
portion of gram- negative and gram-positive bacterial causes of VAP. We found a much lower
proportion of gram-positive organisms as a causative agents of VAP and non VAP [35, 36].
ICUs often have the highest levels of infections due to antimicrobial resistant pathogens as
a result of the environment that is under constant pressure with high antimicrobial usage due
to the presence of severely ill patients. Etiologic agents of VAP are generally associated with
pathogens with high levels of antimicrobial resistance, resulting in the need to treat with
broad-spectrum antibiotics, which further drives antibiotic resistance [12].
Early onset VAP is usually attributed to antibiotic sensitive pathogens whereas late onset
VAP is more likely caused by MDR bacteria and emerges after 4 days of intubation [37, 38].
However, this scenario seems to be different in the LMIC settings. This study revealed that
MDR isolates were slightly higher in VAP than in non-VAP categories. Although significant
association was not observed, there was an indication of association of VAP with MDR organ-
isms. This further highlights the need to have infection control protocol guidelines in order to
control such HAIs. s Guidelines for VAP prevention, including hand washing, elevation of the
head of the bed, oral care with chlorhexidine, optimized endotracheal tube cuff pressure, respi-
ratory circuit manipulation, and weaning protocols to early extubation were established in our
hospital. These are cost effective control and preventive measures of VAP. Strict compliance,
staff training, and regular monitoring of implementation of such guidelines will be effective in
the prevention of VAP.
Mortality attributable to HAP is estimated between 5 and 13% [39].Even in HAP, generally
considered to be less severe than VAP, serious complications occur in approximately 50% of
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patients [40].Mortality was significantly higher in patients with pneumonia requiring intuba-
tion (44.6%, 86/193) than patients with pneumonia without intubation (10.7%, 13/122, p<
0.001). Highest mortality of 58.5% (24/41) was observed among VAP patients (I+P+V+) fol-
lowed by non VAP (I+P+V-) patients (40.8%,62/152) and lowest mortality of 3.7% (4/109) was
observed among patients who neither required intubation nor had pneumonia during their
stay in the ICU (I-P-V-) category. The mortality in our ICU due to VAP was still lower than
reported in other studies where it was as high as 68.4% [31].
Development of pneumonia increased the number of days of intubation. Intubated patients
with pneumonia had to spend a median of 7.5(4–11) (I+P+V-) to 17(11–27) (I+P+V+) days
being intubated as in comparison to those without pneumonia (I+P-V-) {4(2.75 to 7.25)}. In
addition, VAP confirmed patients spent a median of16 days in ICU ranging from 10 to 27
days.24.6% (50 / 203) patients required intubation due to the reduction in exchange of oxygen
(low PaO2), followed by cognitive impairment and airway obstruction (19.2%, 39/203).
Conclusion
Pneumonia was one of the common infections in our ICU setting. Pneumonia developed
among intubated patients in the ICU had longer days of stay in the ICU when compared to
non-intubated patients with pneumonia. We found high VAP incidence in this study and
highest mortality was observed among VAP patients followed by non VAP (I+P+V-) patients.
MDR Gram negative bacteria were the dominant organisms from both VAP and non-VAP
categories.
HAP including VAP remains to be the most prevalent HAIs at Patan hospital. One of the
limitations of this study was that it was conducted at a single hospital. Surveillance studies on
HAIs at various hospitals within the country are required in identifying the etiological agents.
Antimicrobial susceptibility profiles of the etiological agents and outcomes of HAP and VAP
would be beneficial for setting more appropriate guidelines for management of such diseases.
In addition, countries like Nepal lack proper protocols of infection control and implementa-
tion for minimizing such infections in the hospital. Therefore, a suitable surveillance programs
should be implemented, analyzing differences in VAP rates between different ICUs, and evalu-
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